促进先天性心脏病儿童的临床活动:随机临床试验
Patricia E Longmuir1, Jane Lougheed2, Andrew S Mackie3
1Children's Hospital of Eastern Ontario Research Institute and University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
CJC pediatric and congenital heart disease
|September 11, 2025
概括
一项新的临床咨询干预措施改善了先天性心脏病儿童的身体活动. 这种方法对临床医生来说是可行的,并帮助孩子实现日常活动目标.
科学领域:
- 儿科 儿科 儿科
- 心脏病学 心脏病学
- 运动科学 运动科学
背景情况:
- 患有先天性心脏病 (CHD) 的儿童需要有效的策略来促进身体活动.
- 当前的临床实践往往不足以促进儿童心血管疾病患者的推体育活动.
- 需要可行的干预措施,临床医生可以将其整合到常规护理中.
研究的目的:
- 评估对中度至重度心血管疾病的儿童进行简短的临床体育活动咨询干预的可行性和有效性.
- 评估干预措施对6个月的日常体力活动水平的影响.
- 确定医疗保健系统的影响,包括临床医师的合规性和患者的看法.
主要方法:
- 一项务实,单盲,多中心随机临床试验,涉及155名患有心脏病的儿童 (5-17岁).
- 干预组在诊所访问期间接受了标准化咨询和运动学家支持.
- 主要结果:每天6个月的步数计测量步数;次要结果:咨询率,访问长度,感知,推.
主要成果:
- 干预组参与者维持了每天超过12,000步的活动,而对照组的活动在第5个月显著下降.
- 基线高度活跃的参与者在两组中都保持了他们的活动水平.
- 这项干预是可行的,97%的参与者接受了咨询,诊所访问时间没有增加.
结论:
- 一个简短的,标准化的临床咨询干预与动理学支持有效地增加和保持心脏病儿童的身体活动.
- 这种干预对临床医生来说是可行的,使得他们能够遵守推的活动促进指南.
- 这种方法可以帮助患有心脏病的儿童达到推的每日体力活动水平.
相关概念视频
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
01:16Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
01:26Coronary Artery Disease IV: Preventive Measures
591
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
591
01:30Acute Coronary Syndrome III: Diagnostic Studies
219
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
219
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
466
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466